Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Thoracic 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Imatinib Mesylate 3nilotinib 2Sunitinib 2Ibandronic Acid 2Doxorubicin 2Cyclophosphamide 2regorafenib 1pegylated granulocyte colony-stimulating factor 1nirogacestat 1avapritinib 1anlotinib 1Zoledronic Acid 1Tranexamic Acid 1Thiotepa 1Ritonavir 1Radiotherapy 1Pregabalin 1Oxaliplatin 1Nevirapine 1Midazolam 1Lopinavir 1Lithium Carbonate 1Lead 1Kyphoplasty 1Indocyanine Green 1Ifosfamide 1Hyperbaric Oxygenation 1Filgrastim 1Esomeprazole 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Midazolam × Sarcoma × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡